Efficacy and Safety of Lorlatinib in ALK+ NSCLC - 102164

Spotlight
Video

Efficacy and Safety of Lorlatinib in ALK+ NSCLC

Loading........
Description: H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a third generation ALK inhibitor, lorlatinib, for ALK positive non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 9006: Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
Shared By : AnnualMeeting2017
Posted on : 06/16/17
Added : 10 months ago